There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Complement Component C5a

Complement Component C5a

Brief Information

Name:C5a anaphylatoxin chemotactic receptor
Target Synonym:Receptor, Anaphylatoxin C5a,C5a-R,Complement Component 5 Receptor 1 (C5a Ligand),C5a Anaphylatoxin Chemotactic Receptor,C5AR,Complement C5a Receptor 1,Complement Component 5a Receptor 1,C5a Anaphylatoxin Chemotactic Receptor 1,C5a Anaphylatoxin Receptor,C
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data

C5A-H5116-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human C5a, Tag Free (Cat. No. C5A-H5116) induce N-acetyl-β-D-glucosaminidase release from differentiated U937 cells. The ED50 for this effect is 0.215-0.323 μg/mL (Routinely tested).

Cynomolgus C5a, Tag FreeCynomolgus C5a, Tag Free (Cat. No. C5A-C5118) ELISA bioactivity

Immobilized Cynomolgus C5a, Tag Free (Cat. No. C5A-C5118) at 2 μg/mL (100 μL/well) can bind Anti-C5a (Human IgG1) with a linear range of 0.8-13 ng/mL (QC tested).

Human C5a, Fc Tag (Cat. No. ) MALS images

The purity of Human C5a, Fc Tag (Cat. No. C5A-H525a) was more than 90% and the molecular weight of this protein is around 80-90 kDa verified by SEC-MALS.

Human C5a, Fc TagHuman C5a, Fc Tag (Cat. No. C5A-H525a) ELISA bioactivity

Immobilized Human C5a, Fc Tag (Cat. No. C5A-H525a) at 2 μg/mL (100 μL/well) can bind Anti-C5a (Human IgG1) with a linear range of 2-16 ng/mL (QC tested).

Customer Reviews

Synonym Name

C5a,Complement Component 5a


Human Complement Component C5a (C5a) is also known as C5,and is a protein fragment released from complement component C5.,is a potent chemotactic factor for human peripheral blood neutrophils and monocytes, and is believed to play an important role in a number of inflammatory conditions. There are several functions in the below: C5a is an anaphylatoxin, causing the release of histamine from mast cells; C5a is effective leukocyte chemoattractants, causing the accumulation of white blood cells, especially neutrophil granulocytes, at sites of complement activation; C5a activates white blood cells by increasing avidity for white blood cell integrins and upregulating the Lipoxygenase pathway for arachidonic acid metabolism; C5a is a powerful inflammatory mediator, and seems to be a key factor in the development of pathology of many inflammatory diseases involving the complement system; C5a modulates balance between activating versus inhibitory IgG Fc receptors on leukocytes, thereby enhancing autoimmune response.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Avdoralimab NN-8210; IPH-5401; Anti-C5aR-215; NNC-0215-0384 Phase 2 Clinical Novo Nordisk A/S Neoplasms; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Inflammation Details
Avacopan CCX-168 Phase 3 Clinical Chemocentryx Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Glomerulonephritis, IGA; Vasculitis; Glomerulonephritis, Membranoproliferative; Hidradenitis Suppurativa Details
TJ-210001 MOR-210; MOR044254; TJ 210; TJ210001; WBP-2191; TJ-210001; TJ-210; MOR-044254 Phase 1 Clinical I-Mab Biopharma Co Ltd, Morphosys Solid tumours; Neoplasm Metastasis Details

This web search service is supported by Google Inc.